Jupiter Topco LLC Acquires Shares of 6,307,636 CAMP4 Therapeutics Corporation $CAMP

Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,307,636 shares of the Wireless communications provider’s stock, valued at approximately $27,581,000. Jupiter Topco LLC owned 10.05% of CAMP4 Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of CAMP. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $25,647,928. BlackRock Inc. acquired a new position in CAMP4 Therapeutics in the 2nd quarter worth about $7,185,000. Deutsche Bank AG purchased a new position in CAMP4 Therapeutics during the second quarter worth approximately $138,000. Bank of New York Mellon Corp purchased a new position in CAMP4 Therapeutics during the second quarter worth approximately $365,000. Finally, Bank of America Corp DE grew its holdings in CAMP4 Therapeutics by 141,700.0% in the first quarter. Bank of America Corp DE now owns 31,196 shares of the Wireless communications provider’s stock valued at $138,000 after purchasing an additional 31,174 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.56.

Insider Buying and Selling

In other news, Director Richard A. Young purchased 16,378 shares of the stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the transaction, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. This represents a 9.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Andrew J. Schwab sold 114,700 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the sale, the director directly owned 2,465,298 shares of the company’s stock, valued at $11,192,452.92. The trade was a 4.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have purchased 36,031 shares of company stock valued at $59,451 and have sold 193,613 shares valued at $888,037. Company insiders own 21.69% of the company’s stock.

CAMP4 Therapeutics Price Performance

Shares of CAMP4 Therapeutics stock opened at $4.15 on Friday. The stock has a market capitalization of $260.41 million, a P/E ratio of -1.79 and a beta of 0.22. The business has a 50 day simple moving average of $4.13 and a two-hundred day simple moving average of $4.36. CAMP4 Therapeutics Corporation has a 12 month low of $1.41 and a 12 month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The firm had revenue of $1.78 million during the quarter. As a group, research analysts anticipate that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current fiscal year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.